Every 8-K that Ironwood Pharmaceuticals, Inc. (IRWD) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IRWD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IRWD filings page.
Ironwood Pharmaceuticals reported strong Q2 2026 results and raised its full‑year 2026 financial guidance. Total revenue was $113 million compared with $85 million in Q2 2025, driven largely by LINZESS® performance. GAAP net income was $51 million, or $0.31 per diluted share, versus $23.6 million, or $0.14, a year earlier. Adjusted EBITDA was $83 million, up from $50.1 million in Q2 2025.
LINZESS U.S. net sales were $282 million in the quarter and $555 million year‑to‑date, representing 44% year‑over‑year growth. Reflecting this, 2026 LINZESS U.S. net sales guidance increased to $1.15–$1.20 billion (greater than 30% growth year‑over‑year), total revenue guidance to $460–$485 million, and adjusted EBITDA guidance to more than $310 million. Ironwood also repaid $200 million of convertible notes using cash on hand, and initiated the confirmatory Phase 3 STARS‑2 trial of apraglutide in short bowel syndrome with intestinal failure, which is now actively recruiting patients.
Ironwood Pharmaceuticals, Inc. reported that stockholders approved an amendment to its Amended and Restated 2019 Equity Incentive Plan at the 2026 Annual Meeting of Stockholders. The amendment increases the number of shares of Class A common stock available for issuance under the plan by 10,000,000 shares, expanding the pool for future equity-based compensation grants.
Stockholders also voted on the election of directors and other proposals, with each director nominee receiving over 104 million votes in favor and substantial broker non-votes recorded. Additional proposals received support levels including 104,461,936 votes for one item and 121,957,895 votes for another, indicating strong overall approval.
Ironwood Pharmaceuticals, Inc. reported that on June 15, 2026 it repaid in full the $200.0 million aggregate principal amount of its 1.50% convertible senior notes due 2026 at their scheduled maturity. The repayment was funded entirely from available cash on hand.
No noteholders elected to convert the 2026 convertible notes into equity, and the capped call transactions entered into in connection with the original issuance of these notes terminated upon expiry.
Ironwood Pharmaceuticals amends a prior report to detail compensation for Ronald Silver in his new role as interim chief financial officer and principal financial officer. Effective with this role, the board’s Compensation and HR Committee approved a monthly interim assignment fee of $12,250 for Mr. Silver.
On May 19, 2026, Mr. Silver also received a grant of 25,000 restricted stock units under the 2019 Amended and Restated Equity Incentive Plan. These RSUs will vest over two years, with 50% vesting on each approximate anniversary of the grant date, aligning the interim CFO’s pay more closely with the company’s share performance.
Ironwood Pharmaceuticals announced that Senior Vice President and Chief Financial Officer Gregory Martini will resign effective May 15, 2026. The company states his resignation is not due to any disagreement regarding its financial reporting.
Effective the same date, Ronald Silver, age 44, currently Senior Vice President, Corporate Controller and Chief Accounting Officer, will also serve as interim chief financial officer and principal financial officer. Silver has held increasing accounting leadership roles at Ironwood since 2018 and previously worked in accounting and audit roles at Eze Software Group and RSM. The filing notes there is no special arrangement or family relationship related to his selection and no related‑party transactions requiring disclosure.
Ironwood Pharmaceuticals reported a strong turnaround in the first quarter of 2026, with total revenue of $106,506 (thousands), up from $41,143 (thousands) a year earlier. GAAP net income was $40,773 (thousands) versus a prior-year loss, and adjusted EBITDA reached $76,671 (thousands).
Growth was driven by LINZESS, with U.S. net sales of $272,525 (thousands), reflecting 97% year-over-year growth and 5% demand growth. The company maintained 2026 guidance, including U.S. LINZESS net sales of $1.125–$1.175 billion and adjusted EBITDA above $300 million.
Ironwood highlighted a planned confirmatory Phase 3 trial of apraglutide in short bowel syndrome and an FDA priority review of a LINZESS sNDA in younger pediatric patients, with a PDUFA date set for May 24. Management expects strong first-quarter revenue to support repayment of 2026 convertible notes at maturity in June.
Ironwood Pharmaceuticals, Inc. reported that it has met the liquidity conditions tied to the “Maturity Date” definition in its existing Credit Agreement with Wells Fargo Bank, National Association, as administrative agent. As a result, the revolving credit facility’s maturity date remains December 31, 2028, under the current terms of the Credit Agreement.
Ironwood Pharmaceuticals reported fourth-quarter and full-year 2025 results and reaffirmed a strong 2026 outlook. For 2025, total revenue was $296.2M, GAAP net income was $24.0M and adjusted EBITDA reached $138.1M. The company generated $127M in operating cash flow and ended the year with $215.5M in cash and cash equivalents.
LINZESS delivered 11% full-year EUTRx demand growth, remaining the leading U.S. prescription brand for IBS-C and CIC. For 2026, Ironwood expects U.S. LINZESS net sales of $1.125–$1.175B, total revenue of $450–$475M and adjusted EBITDA of more than $300M, while it advances the apraglutide Phase 3 STARS-2 trial in short bowel syndrome with intestinal failure.
Ironwood Pharmaceuticals reported that the U.S. Department of Health and Human Services has set the Medicare “Maximum Fair Price” for LINZESS (linaclotide) at $136 for a 30-day equivalent supply. This Maximum Fair Price will become the new Medicare net price starting January 1, 2027 under the Inflation Reduction Act of 2022.
The company states that this revised price for LINZESS is in line with its expectations, indicating the decision aligns with its planning around the product’s U.S. Medicare pricing.
Ironwood Pharmaceuticals (IRWD) furnished an Item 2.02 Form 8-K announcing a press release with an update on recent business activities and results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1 and incorporated by reference. The information is furnished, not filed, under the Exchange Act.
Ironwood Pharmaceuticals, Inc. reported that Andrew Dreyfus has notified the company of his resignation from its Board of Directors. His resignation is effective November 1, 2025.
The company explains that Mr. Dreyfus is stepping down because he has been appointed President and Chief Executive Officer of the National Institute for Health Care Management (NIHCM) Foundation. It states that his decision to resign is not due to any disagreement with Ironwood regarding its operations, policies, or practices.
Ironwood expresses appreciation for Mr. Dreyfus’s service and notes his contributions during his tenure on the Board of Directors.
Ironwood Pharmaceuticals, Inc. reported that it has regained compliance with the Nasdaq Global Select Market’s minimum bid price requirement. On August 29, 2025, Nasdaq notified the company that its Class A common stock again meets Nasdaq Listing Rule 5450(a)(1), which requires a minimum bid price of $1.00 per share for at least 10 consecutive business days. With this condition satisfied, the prior deficiency notice has been resolved and the matter is now closed, removing the immediate risk of delisting tied to bid price.